ImageneBio, Inc.
NasdaqCM · USDImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Analytick AI is a research platform. Output is informational and not financial advice — trade at your own risk.
Analytick AI is a product of Analytick Inc. · Rockville, Maryland, 20852, United States
© 2026 Analytick AI
Be the first to share your outlook and start the conversation with other investors in the IMA community.